An Idyllic time

Investors in Biocartis S.A. were unfazed by a delayed launch date for the Swiss company's Idylla Multiplex Biomarker Analysis Platform for molecular diagnostics, as evidenced by this month's €30 million ($40.5 million) series E round. The existing investors are betting the company's pipeline of assays and ability to process any sample type will ensure its long-term competitiveness.